Latest valproic acid Stories
SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, today announced it has closed a $60 million Series C financing.
The mice obtained by researchers at UAB, in addition to being the first of their species cloned in Spain, are the first animals to survive at birth and develop correctly.
- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis.
RESEARCH TRIANGLE PARK, N.C., June 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
- Easy-to-swallow formulation provides important new alternative for patients RESEARCH TRIANGLE PARK, N.C., May 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
- Company preparing to initiate phase III clinical trial - SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that HPN-100 has received orphan product designation from the U.S.
New guidelines developed by the American Academy of Neurology and the American Epilepsy Society show it's relatively safe for women with epilepsy to become pregnant, but caution must be taken, including avoiding one particular epilepsy drug that can cause birth defects.
Abstract #4061 DENVER, April 21 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data today at the American Association for Cancer Research's 100th Annual Meeting 2009 that could potentially provide a brighter future for children who suffer from a more deadly form of acute leukemia. (Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO) Yubin Ge, Ph.D., and Chengzhi Xie, Ph.D., presented a poster at the conference...
Canadian researchers found immigrant women less likely than others to be taking folic acid before pregnancy to help prevent spina bifida and anencephaly. Neural tube defects -- birth defects of the spinal cord and brain, known as spina bifida and anencephaly -- can be reduced by nearly 50 percent with folic acid supplements taken just before and soon after conception. The study found 60 percent of Canadian-born women in the study reported using folic acid supplements in the three-month period...
- An armed gangster.